Stockscreener 앱 받기
48.62
3.31%
1.56
전일 마감가:
$47.06
열려 있는:
$47.06
하루 거래량:
956.44K
Relative Volume:
0.50
시가총액:
$3.37B
수익:
$18.09M
순이익/손실:
$-208.87M
주가수익비율:
-13.84
EPS:
-3.5125
순현금흐름:
$-178.15M
1주 성능:
+4.74%
1개월 성능:
+17.10%
6개월 성능:
+137.17%
1년 성능:
+208.11%
1일 변동 폭
$46.31
$48.70
1주일 범위
$44.22
$48.70
52주 변동 폭
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
명칭
Uniqure Nv
전화
1-339-970-7000
주소
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
48.62 | 3.13B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2026-03-09 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2026-03-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | 개시 | Wolfe Research | Peer Perform |
| 2026-01-28 | 개시 | Barclays | Equal Weight |
| 2025-11-04 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-04-01 | 재개 | Chardan Capital Markets | Buy |
| 2024-12-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-02-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-17 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-01 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-24 | 개시 | H.C. Wainwright | Buy |
| 2020-11-11 | 개시 | Berenberg | Buy |
| 2020-11-09 | 개시 | Jefferies | Buy |
| 2020-11-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-08-25 | 개시 | Raymond James | Strong Buy |
| 2020-07-31 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-06-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | 개시 | Cowen | Outperform |
| 2019-12-03 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | Credit Suisse | Outperform |
| 2019-10-11 | 개시 | Stifel | Buy |
| 2019-09-25 | 개시 | Bernstein | Outperform |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-07-30 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-07-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
모두보기
Uniqure Nv 주식(QURE)의 최신 뉴스
uniQure (NASDAQ:QURE) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Susquehanna entities (QURE) disclose 3.34M-share, 4.8% position in uniQure - Stock Titan
RTW Investments (QURE) discloses 3.94M-share beneficial stake in uniQure N.V. - Stock Titan
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $71 - Moomoo
uniQure (QURE) Q2 2026 Earnings Call Transcript - AOL.com
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
Hennion & Walsh Asset Management Inc. Increases Holdings in uniQure N.V. $QURE - MarketBeat
Assenagon Asset Management S.A. Has $23.65 Million Position in uniQure N.V. $QURE - MarketBeat
Why uniQure (QURE) Is Up 6.4% After FDA Alignment On Accelerated AMT-130 Approval Path - simplywall.st
Uniqure NV (QURE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Uniqure NV (QURE) Stock News Today - TradingKey
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
UniQure N.V. (QURE) Stock Analysis: Exploring A 53.35% Potential Upside In Gene Therapy - DirectorsTalk Interviews
uniQure N.V. (NASDAQ:QURE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
QURE|Uniqure NV|Price:44.206|Chg%:-0.034 - TradingKey
Weekly Recap: AMT-130 readout and Wells Fargo raises QURE target to $75 - TradingView
uniQure N.V. (QURE) Stock Analysis: Assessing Upside Potential and Analyst Confidence in Biotech Innovator - DirectorsTalk Interviews
uniQure: 'Hold' AMT-130 U-Turn By FDA For HD Could Possibly Alter Course (NASDAQ:QURE) - Seeking Alpha
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y - TradingView
Will QURE’s AMT-130 Regulatory Momentum Offset Mounting Losses And Share Dilution Risk? - webull.com
Uniqure NV earnings missed by $0.38, revenue topped estimates - Investing.com Nigeria
uniQure N.V. 2026: Revenue $5.84M, EPS ($1.22) — 10-Q Summary - TradingView
UniQure: Q2 Earnings Snapshot - 10tv.com
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update - GlobeNewswire
UniQure 2Q Loss $81.1M >QURE - Moomoo
uniQure earnings in focus as AMT-130 gene therapy BLA looms By Investing.com - Investing.com Australia
uniQure earnings in focus as AMT-130 gene therapy BLA looms - Investing.com
Uniqure NV (QURE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Uniqure NV (QURE) Income Statement - TradingKey
Uniqure NV (QURE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Uniqure NV (QURE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kalehua Capital Management LLC Makes New Investment in uniQure N.V. $QURE - MarketBeat
Orbimed Advisors LLC Has $34.93 Million Holdings in uniQure N.V. $QURE - MarketBeat
Uniqure NV (QURE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Uniqure NV (QURE) Balance Sheet - TradingKey
QURE|Uniqure NV|Price:38.230|Chg%:-0.740 - TradingKey
Uniqure NV (QURE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Uniqure NV (QURE) Cash Flow - TradingKey
uniQure N.V. Revenue Breakdown – FWB:UQ1 - TradingView
uniQure (QURE) to Release Earnings on Wednesday - MarketBeat
uniQure N.V. Revenue Breakdown – BIVA:QURE/N - TradingView
Siren L.L.C. Makes New $16.35 Million Investment in uniQure N.V. $QURE - MarketBeat
uniQure N.V. (QURE) Stock Analysis: Exploring a 63.82% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Aberdeen Group plc Reduces Holdings in uniQure NV - GuruFocus
Uniqure NV (QURE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Earnings Preview: UniQure NV to Report Financial Results Pre-market on July 29 - Moomoo
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or uniQure N.V. Stock? - AAII
Militia Capital Management LLC Purchases New Shares in uniQure N.V. $QURE - MarketBeat
uniQure N.V. to announce Q2 2026 financial results on July 29 - scanx.trade
Uniqure Nv (QURE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):